Drug intelligence / Profile preview

SLM0807

Development stage: Unknown
Lead developer: HK inno.N Corporation
Modality: Small Molecules
Administration: Oral

Overview

SLM0807 is an investigational drug studied primarily in the context of diabetes mellitus. It has been evaluated in multiple phase 1 clinical trials, often in combination with HKB0701 or as part of a fixed-dose combination (CJ30001), to assess its pharmacokinetics and pharmacodynamics. The specific mechanism of action, molecular target, and chemical class of SLM0807 are not disclosed in publicly available sources. The drug has been developed by HK inno.N Corporation and CJ Cheiljedang Corp., with studies focusing on healthy volunteers to determine safety, bioequivalence, and interaction profiles[1][2][3][6].

Beyond the preview

Go deeper on SLM0807.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLM0807.

Explore the full profile